(Bloomberg) — President Donald Trump credited Regeneron Pharmaceutical Inc.’s experimental monoclonal antibody treatment with his apparent recovery from the coronavirus, and announced Wednesday his intention to authorize emergency use of the therapeutic and provide it free to Americans.“I want everybody to be given the same treatment as your president, because I feel great,” Trump said […]

Trump’s doctor said on Friday that the president is being treated with Regeneron’s experimental drug aimed at supplying antibodies to help fight his coronavirus infection.

As President Trump tests positive for coronavirus, investors and health officials worry over the state of the vaccine race and testing. Dr. Isaac Bogach, an Infectious Diseases Specialist, joins The Final Round to discuss his thoughts on the latest developments with the coronavirus and the vaccine race.

Levels of an antibody found in recovered COVID-19 patients fell sharply 2 to 3 months after infection for both symptomatic and asymptomatic patients, according to a Chinese study.

Eleven out of 12 severely or critically ill coronavirus patients given lenzilumab at the Mayo Clinic were discharged from the hospital in an average of five days, without side effects, new data shows.

The test is produced by Abbott, which was the second antibody test approved by ministers after Roche. Blood samples have to be posted to a laboratory, therefore it isn’t a ‘DIY’ test.

Scientists discovered an antibody that inhibits the family of coronaviruses, including COVID-19 and SARS. It works by disabling the ‘spike proteins’ the coronavirus uses to infect human cells.

The new test produced by Abbott has been approved by Public Health England after one produced by Roche Diagnostics was ratified two days ago. The Department of Health is in talks with both firms.

Roche Diagnostics has finally created a kit that is accurate enough to be used at scale – and the firm says it has enough stock to provide hundreds of thousands to the NHS every week.